This protocol addresses primary cutaneous anaplastic large cell lymphoma (PC-ALCL) presenting with multifocal skin lesions. The multifocal nature of skin involvement is a key factor that shapes the treatment approach and distinguishes this presentation from limited or solitary disease.
The management of PC-ALCL with multifocal skin lesions includes a targeted systemic agent. The full protocol defines the specific therapy, the clinical circumstances under which it is applied, and relevant sequencing considerations.
Patients presenting with multifocal skin lesions can best be treated with low-dose MTX, as in LyP [IV, A], or with RT [IV, A] in the case of only a few lesions.
BV should be considered in cases with multifocal skin lesions refractory to conventional therapies and in patients developing extracutaneous disease [II, B].
View source ↗